{"id":"active-bevacizumab-and-active-dexamethasone","safety":{"commonSideEffects":[{"rate":null,"effect":"Intraocular inflammation"},{"rate":null,"effect":"Elevated intraocular pressure"},{"rate":null,"effect":"Cataract progression"},{"rate":null,"effect":"Endophthalmitis"},{"rate":null,"effect":"Systemic corticosteroid effects (with repeated dosing)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Bevacizumab is a monoclonal antibody that blocks VEGF signaling, which drives pathological neovascularization in retinal diseases. Dexamethasone is a corticosteroid that reduces inflammatory cytokines and edema. Together, they target both the angiogenic and inflammatory components of retinal pathology, particularly in conditions like diabetic macular edema or retinal vein occlusion.","oneSentence":"This combination uses bevacizumab to inhibit vascular endothelial growth factor (VEGF) and reduce abnormal blood vessel formation, while dexamethasone suppresses inflammation in the eye.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:18:55.578Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Retinal diseases with abnormal neovascularization and inflammation (e.g., diabetic macular edema, retinal vein occlusion)"}]},"trialDetails":[{"nctId":"NCT01295112","phase":"PHASE2, PHASE3","title":"Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion","status":"COMPLETED","sponsor":"Texas Retina Associates","startDate":"2011-05","conditions":"Non-Ischemic Central Retinal Vein Occlusion","enrollment":68}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Avastin® (bevacizumab)","Ozurdex® (dexamethasone intravitreal implant)"],"phase":"phase_2","status":"active","brandName":"Active bevacizumab and Active dexamethasone","genericName":"Active bevacizumab and Active dexamethasone","companyName":"Texas Retina Associates","companyId":"texas-retina-associates","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses bevacizumab to inhibit vascular endothelial growth factor (VEGF) and reduce abnormal blood vessel formation, while dexamethasone suppresses inflammation in the eye. Used for Retinal diseases with abnormal neovascularization and inflammation (e.g., diabetic macular edema, retinal vein occlusion).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}